摘要
目的:观察趋化因子CCL25和CX3CL1在正常肝组织和肝纤维化与肝硬化病人肝组织中的表达变化。方法:ELISA法测定9例正常肝组织和10例肝纤维化与11例肝硬化病人肝组织中CCL25和CX3CL1的含量。结果:CCL25在正常肝组、肝纤维化组和肝硬化组的含量分别为(4.06±2.23)、(14.46±4.10)和(21.97±2.98)ng/g。肝硬化组的含量显著高于正常肝组和肝纤维化组,肝纤维化组的含量又显著高于正常肝组。CX3CL1在正常肝组、肝纤维化组和肝硬化组的的含量分别为(4.84±3.72)、(13.72±5.59)和(14.70±3.52)ng/g。肝纤维化组和肝硬化组的含量均显著高于正常肝组,但肝纤维化组与肝硬化组的含量差异无统计学意义。结论:趋化因子CCL25和CX3CL1在人的正常肝组织中有表达,但表达的数量水平较低。肝脏发生纤维增生性损伤时,肝内CCL25和CX3CL1的含量都显著增加,随着病变由肝纤维化向肝硬化阶段发展,肝内CCL25和CX3CL1的含量呈现出不同变化,CCL25表现为进一步升高,CX3CL1表现为在高水平维持。
Objective ：To investigate the intrahepatic level of chemokine CCL25 and CX3CL1 in normal human and pa- tients with hepatic fibrosis and cirrhosis. Methods：Hepatic tissues were obtained in surgery from 9 normal persons, 10 patients with fibrotic liver, 11 patients with cirrhosis. The content of CCL25 and CX3CL1 in hepatic tissue was assayed by ELISA. Results ： The concentrations of CCL25 and CX3CL1 were （4.06 ± 2.23 ） and （4.84± 3.72 ） ng/g in normal liv- er, （ 14.46 ±4.10） and （ 13.72 ±5.59） ng/g in fibrotic liver, （21.97 ± 2.98） and （ 14.70 ± 3.52） ng/g in cirrho- sis. Tile level of CCL25 in selerous liver was remarkably higher than that in normal and fibrotic liver, and the level of CCL25 in fibrotic liver was remarkably higher than that in normal liver. The level of CX3CL1 in fibrotic liver and selerous liver were remarkably higher than those in normal liver, but there was no significant difference between fibrotic liver and sclerous liver. Conclusion：The ehemokines CCL25 and CX3CL1 were expressed in the normal liver and fibrotie live as well as sclerous liver in human. With the aggravation of hepatic fibrous degeneration, intrahepatic level of CCL25 was el- evated further, high expression of CX3CL1 in fibrous liver was kept until cirrhosis stage.
出处
《赣南医学院学报》
2010年第4期540-542,共3页
JOURNAL OF GANNAN MEDICAL UNIVERSITY
基金
广州市科技攻关计划项目(2007Z3-E0371)
